RILVEGOSTOMIG
UNII YSL2GUT2Q8

Substance Identification & Data

This profile provides standardized clinical and technical data for Rilvegostomig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) YSL2GUT2Q8.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2640305-01-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

YSL2GUT2Q8

CAS Registry Number

2640305-01-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RILVEGOSTOMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C188211

National Cancer Institute reference terminology for clinical and research data.

INN ID

12387

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-167

Identifier assigned by the United States Adopted Names Council.

Substance Type

Rilvegostomig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Rilvegostomig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Rilvegostomig

Common Names & Synonyms

RILVEGOSTOMIG [USAN]

Rilvegostomig [WHO-DD]

immunoglobulin G1-kappa/lambda, anti-[Homo sapiens PDCD1(programmed cell death 1, PD1, PD-1, CD279)] and anti-[Homo sapiens TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], humanized and Homo sapiens monoclonal antibody, bispecific; gamma1 heavy chain anti-PDCD1 (1-452) [VH humanized (Homo sapiens IGHV3-48*01 (92.9%) -(IGHD) -IGHJ4*01 (93.3%) L123>T (117), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v39 CH2 F1.3, E1.2, S116, G1v33 CH3 S22, A24, V86 (hole) (CH1 R120 (219) (123-220), hinge 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), P116>S (336) (236-345), CH3 Y5>C (354), E12 (361), M14 (363), T22>S (371), L24>A(373), Y86>V (412) (346-450), CHS (451-452)) (123-452)], (225-219')-disulfide with kappa light chain anti-PDCD1 (1'-219') [V-KAPPA humanized (Homo sapiens IGKV3D-7*01 (81.1%) -IGKJ2*02 (100%), CDR-IMGT [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; gamma1 heavy chain anti-TIGIT (1''-451'') Homo sapiens [VH (Homo sapiens IGHV3-30*01 (96.9%) -(IGHD) -IGHJ6*01 (94.4%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1''-121'') -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v32 CH3 W22 (knob) (CH1 F5>C (130), R120 (218) (122''-219''), hinge 1-15 C5>V (224) (220''-234''), CH2 L1.3>F (238), L1.2>E (239), P116>S (335) (235''-344''), CH3 S10>C (358), E12 (360), M14 (362), T22>W (370) (345''-449''), CHS (450''-451'')) (122''-451'')], (130''-125''')-disulfide with lambda light chain anti-TIGIT (1'''-219''') Homo sapiens [V-LAMBDA (Homo sapiens IGLV1-44*01 (92.6%) -IGLJ7*01 (90%) F118>L (101) , CDR-IMGT [8.3.11] (26-33.51-53.90-100)) (1'''-110''') -Homo sapiens IGLC2*01 (98.1%) S10>C (125), C126>V (215) (111'''-216''')]; heterodimer (231-230'':234-233'': 354-358'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-CAT-S, glycoform alfa

rilvegostomig [INN]